Preferences help
enabled [disable] Abstract
Number of results
2011 | 6 | 2 | 193-200
Article title

CSF and serum total-tau and phospho-tau(181P) in MS patients

Title variants
Languages of publication
In search of biological marker in multiple sclerosis (MS), total-tau and phospho-tau (Thr181) concentrations were established in CSF and serum of 78 patients with MS, using commercially available kits. Serum and CSF concentrations of IgG, IgM, and albumin were assayed simultaneously to calculate quotients and indices of intrathecal synthesis. Serum t-tau detection was strikingly low (23.1%); therefore, this factor was excluded from further analysis. Serum p-tau levels did not correlate with any of indices or quotients. Unexpectedly, CSF t-tau and p-tau showed an inverse relation with MSSS and EDSS, which has not been published elsewhere. Our results do not support utility of serum t-tau and p-tau as surrogate markers for MS.
Physical description
1 - 4 - 2011
17 - 2 - 2011
  • Department of Neurology, Medical University of Lublin, 20-954, Lublin, Poland
  • 2nd Department of Anaesthesiology and Intensive Care, Medical University of Lublin, 20-081, Lublin, Poland
  • Department of Neurology, Medical University of Lublin, 20-954, Lublin, Poland
  • [1] De Stefano N., Matthews P. M., Fu L., Narayanan S., Stanley J., Francis G. S., Antel J. P. et al., Axonal damage correlates with disability in patients with repalsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study, Brain, 1998; 121, 1469–1477[Crossref]
  • [2] Roxburgh R. H., Seaman S. R., Masterman T., Hensiek A. E., Sawcer S. J., Vukusic S. et al., Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity, Neurology, 2005, 64, 1144–1151 [Crossref]
  • [3] Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 1983, 33, 1444–1452 [Crossref]
  • [4] Pachner A. R., Steiner I., The multiple sclerosis severity score (MSSS) predicts disease severity over time, J. Neurol. Sci., 2009, 278, 66–70[Crossref]
  • [5] Weingarten M. D., Lockwood A. H., Hwo S-Y., Kirschner M. W., A protein factor essential for microtubule assembly, Proc. Nat. Acad. Sci. USA, 1975, 72, 1858–1862[Crossref]
  • [6] Trojanowski J. Q., Schuck T., Schmidt M. L., Lee V. M., Distribution of tau proteins in the normal human central and peripheral nervous system, J. Histochem. Cytochem., 1989, 37, 209–215 [Crossref]
  • [7] Avila J., Lucas J. J., Perez M., Hernandez F., Role of tau protein in both physiological and pathological processes. Physiol. Rev., 2004, 84, 361–384[Crossref]
  • [8] Ibach B., Binder H., Dragon M., Poljansky S., Haen E., Schmitz E., et al., Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample, Neurobiol. Aging, 2006, 27, 1202–1211[Crossref]
  • [9] Skinningsrud A., Stenset V., Gundersen A. S., Fladby T., Cerebrospinal fluid markers in Creutzfeldt-Jakob disease, Cer. Fluid. Res., 2008, 5, 1–8[Crossref]
  • [10] Süssmuth S. D., Reiber H., Tumani H., Tau protein in cerebrospinal fluid (CSF): a blood-CSF related evaluation in patients with various neurological disease, Neurosci. Lett., 2001, 300, 95–98[Crossref]
  • [11] Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E. et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett., 2001, 297, 187–190[Crossref]
  • [12] Zelman F. P., Jauch E. C., Mulchahey J. J., Gabbita S. P., Rosenberg W. S., Speciale S. al., C-tau biomarker of neuronal damage is severe brain injured patients: association with elevated intracranial pressure and clinical outocome, Brain Res., 2002, 947, 131–139[Crossref]
  • [13] Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P. R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev., 2000, 33, 95–130[Crossref]
  • [14] Hernández F., Pérez M., de Barreda E. G., Goñi-Oliver P., Avila J., Tau as a molecular marker of development, aging and neurodegenerative disorders, Curr. Aging Sci., 2008, 1: 56–61
  • [15] Hein (nee Maier) K., Köhler A., Diem R., Sättler M. B., Demmer I., Lange P. et al., Biological markers for axonal degeneration in CSF and blood of patients with first event indicative for multiple sclerosis, Neurosci. Lett., 2008, 436, 72–76[Crossref][WoS]
  • [16] Reiber H., Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics, Rest. Neurol. Neurosci., 2003, 21: 79–96
  • [17] Polman C. H., Reingold S. C., Edan G., Fillipi M., Hartung H. P., Kappos L. et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“, Ann. Neurol., 2005, 58: 840–846[Crossref]
  • [18] Reiber H., Peter J. B., Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs, J. Neurol. Sci., 2001, 184: 101–122[Crossref]
  • [19] Jiménez-Jiménez F. J., Zurdo J. M., Hernanz A., Medina-Acebrón S., de Bustos F., Barcenilla B. et al., Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis, Acta Neurol. Scand., 2002, 106, 351–354[Crossref]
  • [20] Guimarães J., Cardoso M. J., Sá M. J., Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis, Mult. Scler., 2006; 12, 354–356[Crossref]
  • [21] Valis M., Talab R., Stourac P., Andrys C., Masopust J., Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients, Neuro. Endocrinol. Lett., 2008, 29, 971–976
  • [22] Kapaki E., Paraskevas G. P., Michalopoulou M., Kilidireas K., Increased cerebrispinal fluid tau protein in multiple sclerosis, Eur. Neurol., 2000, 43, 228–232[Crossref]
  • [23] Terzi M., Birinci A., Çetinkaya E., Onar M. K., Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis, Acta Neurol. Scand., 2007, 115, 325–330[Crossref]
  • [24] Brettschneider J., Maier M., Arda S., Claus A., Süssmuth S. D., Kassubek J. et al., Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis, Mult. Scler., 2005, 11, 261–265[Crossref]
  • [25] Rostazy K., Withhut E., Pohl D., Lange P., Cisielcyk B., Diem R. et al., Tau, phospho-tau and S-100B in cerebrospinal fluid of children with multiple sclerosis, J. Child. Neurol., 2005, 20, 822–825
  • [26] Teunissen C. E., Dijkstra C., Polman C., Biological markers in CSF and blood for axonal degeneration in multiple sclerosis, Lancet Neurol., 2005, 4, 32–41[Crossref]
  • [27] Anderson J. M., Patani R., Reynolds R., Nicholas R., Compston A., Spillantini M. G. et al., Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis, Acta Neuropathol., 2009, 117, 583–589[Crossref][WoS]
  • [28] Anderson J. M., Hampton D. W., Patani R., Pryce G., Crowther R. A., Reynolds R. et al., Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis, Brain, 2008, 131, 1736–48[WoS][Crossref]
  • [29] Andersson M., Alvarez-Cermeño J., Bernardi G., Cogato I., Fredman P., Frederiksen J, Fredrikson S. et al., Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report, J. Neurol. Neurosurg. Psychiatry, 1994, 57, 897–902[Crossref]
  • [30] Zemlan F. P., Rosenberg W. S., Luebbe P. A., Campbell T. A., Dean G. E., Weiner N. E. et al., Quantification od axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins, J. Neurochem., 1999, 72, 741–750[Crossref]
  • [31] Ingelson M., Blomberg M., Benedikz E., Wahlund L-O., Karlsson E., Vanmechelen E. et al., Tau immunoreactivity detected in human plasma, but no obvious increase in dementia, Dement Geriatr Cogn Disord, 1999, 10, 442–445[Crossref]
  • [32] Bakshi R., Dandamudi Venkata S. R., Neema M., De C., Bermel R. A., Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis, J Neuroimaging, 2005, 15, 30S–45S[Crossref]
  • [33] Jasperse B., Jakobs C., Eikelenboom M. J., Dijkstra C. D., Uitdehaag B. M. J., Barkhoff F. et al., N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gaschromatography-mass spectrometry, J Neurol, 2007, 254, 631–637[WoS][Crossref]
  • [34] Tenissen C. E., Iacobaeus E., Khademi M., Brundin L., Norgren N., Koel-Simmelink M. J. A. et al., Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis, Neurology, 2009, 72, 1322–1329[WoS][Crossref]
  • [35] Compston A., Lassmann H., Smith K., Differences between acute, relapsing and progressive multiple sclerosis, In: Compston A., Confavreux C., Lassmann H., McDonald I., Miller D., Noseworthy J. et al., McAlpine’s Multiple Sclerosis, 4th Ed., Churchill Livingstone Elsevier, Oxford, UK, 2005, 594–596
  • [36] Ott B. R., Cohen R. A., Gongvatana A., Okonkwo O. C., Johanson C. E., Stopa E. G. et al., Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer’s disease, J Alzheimer Dis, 2010, 20, 647–657
  • [37] Fagan A. M., Head D., Shah A. R., Marcus D., Mintun M., Morris J. C. et al., Decreased CSF Aβ42 correlates with brain atrophy in cognitively normal elderly, Ann Neurol, 2009, 65, 176–183[WoS][Crossref]
  • [38] Tosun D., Schuff N., Truran-Sacrey D., Shaw L. M., Trojanowski J. Q., Aisen P. et al, Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal study, Neurobiol Aging, 2010, 31, 1340–1354[WoS][Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.